A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
A Phase I/II Study to Evaluate the Safety and Efficacy of the MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
Sponsor: MingSight Pharmaceuticals, Inc
Terminated
The study is terminated due to major protocol revisions.
Other terminated trials from MingSight Pharmaceuticals, Inc
More terminations from MingSight Pharmaceuticals, Inc
Other Chronic Lymphocytic Leukemia (CLL) trials with similar outcome
This PHASE1/PHASE2 trial investigates Chronic Lymphocytic Leukemia (CLL) and Diffuse Large B-cell Lymphoma (DLBCL) and is currently terminated or withdrawn. MingSight Pharmaceuticals, Inc leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Status: Recruiting → Terminated
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Feb 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MingSight Pharmaceuticals, Inc
- Shenzhen MingSight Relin Pharmaceutical Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .